Gossamer Bio's stock dropped over 60% after its Phase 3 PROSERA trial for seralutinib failed to meet the primary endpoint. The company had guided investors to expect results in February 2026 with optimism, but did not disclose the trial's stricter statistical significance threshold of 0.025, which was not met despite a p-value of 0.032. This omission led to investor losses and legal inquiries, as the actual trial results would have passed a conventional 0.05 threshold but failed the more stringent requirement. The situation highlights risks in forward guidance when critical trial details are not fully disclosed.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Inseego Corp. will release its financial results for the second quarter of 2026 on August 5, after market close. The company will hold a conference call the same day to discuss the results and business outlook. Investors can access the earnings repor...
